7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,770.35

-26.23

-0.03%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Cingulate Inc. (CINGW)

0.0014 +0.0001 (+7.69%)

At close: November 6 at 12:20:13 PM EST

Loading Chart for CINGW

Chart Range Bar

Interval:

In partnership with ChartIQ

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

CING: Second Quarter Results

CING: Second Quarter Results

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

Cingulate Receives Complete Response Letter from FDA for CTx-1301

Cingulate Receives Complete Response Letter from FDA for CTx-1301

CING: Building Its Cash Position

CING: Building Its Cash Position

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Mobilize your Website

View Site in Mobile | Classic

Share by: